Physician profile
Noah Reiss
NPI 1720061336
$2,105.10
in general payments reported to CMS, 2019-2025
35 companies · $49.97 in 2025
The $49.97 reported for 2025 was less than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $301 · 2020: $220 · 2021: $292 · 2022: $647 · 2023: $432 · 2024: $162 · 2025: $49.97.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $644.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $644.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $545.23 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Astrazeneca Pharmaceuticals LP | $380.38 | 2019-2024 | Fasenra, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $121.97 | 2021-2023 | |
| Teva Pharmaceuticals USA, INC. | $112.55 | 2019-2021 | |
| Eisai INC. | $78.37 | 2020-2021 | |
| Viiv Healthcare Company | $68.74 | 2020-2023 | Rukobia |
| Takeda Pharmaceuticals U.S.A., INC. | $60.68 | 2022 | |
| Amgen INC. | $56.80 | 2022-2023 | Amjevita, Avsola, Enbrel |
| Novartis Pharmaceuticals Corporation | $47.81 | 2019-2025 | |
| Boston Scientific Corporation | $45.46 | 2023 | |
| Pfizer INC. | $45.27 | 2022-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.07 | 2019-2021 | |
| Novo Nordisk INC | $40.36 | 2022-2023 | Rybelsus, Ozempic |
| Lilly USA, LLC | $33.84 | 2022-2023 | Emgality, Jardiance |
| Aimmune Therapeutics, INC. | $30.85 | 2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo Pharmaceuticals INC. | $30.20 | 2019-2022 | |
| Gilead Sciences, INC. | $29.89 | 2022 | |
| Amarin Pharma, INC. | $28.82 | 2019 | |
| Aurinia Pharma U.S., INC. | $28.23 | 2022 | |
| Xeris Pharmaceuticals, INC. | $25.00 | 2022 | |
| Almatica Pharma LLC | $24.14 | 2022 | |
| Grifols USA, LLC | $19.82 | 2019 | |
| Esperion Therapeutics, INC. | $19.38 | 2020 | |
| Paratek Pharmaceuticals, INC. | $19.12 | 2022 | |
| Tetraphase Pharmaceuticals, INC. | $18.86 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $17.71 | 2019 | |
| Dexcom, INC. | $17.59 | 2021 | |
| Seqirus USA INC | $17.58 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $16.67 | 2023 | Uptravi |
| Csl Behring | $14.88 | 2023 | Haegarda |
| Antares Pharma, INC. | $14.20 | 2019 | |
| Philips North America LLC | $13.59 | 2019 | |
| Ibsa Pharma INC. | $12.83 | 2022 | |
| Hologic Sales and Service, LLC | $12.33 | 2019 | |
| Abbvie INC. | $11.88 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Noah Reiss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.